MBL has announced that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chi...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
JSR-AIF participated in the Series D financing of Aillis for the purpose of raising funds to accelerate research and development of AI medical devices, sales, and marketing promotion
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...
With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare ...
1 of 25
Receive JSR Life Sciences news on your RSS reader.